nach oben

Erschienen in:

01.04.2017 | Review Article

Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review

verfasst von: Michele Ghidini, Fausto Petrelli, Jens Claus Hahne, Annamaria De Giorgi, Laura Toppo, Claudio Pizzo, Margherita Ratti, Sandro Barni, Rodolfo Passalacqua, Gianluca Tomasello

Erschienen in: Medical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to collect the available data on central nervous system (CNS) metastases from esophageal and gastric cancer. A PubMed, EMBASE, SCOPUS, Web of Science, LILACS, Ovid and Cochrane Library search was performed. Thirty-seven studies including 779 patients were considered. Among the data extracted, treatment of tumor and brain metastases (BMs), time to BMs development, number and subsite, extracerebral metastases rate, median overall survival (OS) and prognostic factors were included. For esophageal cancer, the median OS from diagnosis of BMs was 4.2 months. Prognostic factors for OS included: performance status, multimodal therapy, adjuvant chemotherapy, single BM, brain only disease and surgery. For gastric cancer, median OS was 2.4 months. Prognostic factors for OS included: recursive partitioning analysis class 2, stereotactic radiosurgery (SRT) and use of intrathecal therapy. HER2-positive gastric cancer was shown to be associated with a higher risk and shorter time to CNS relapse. Patients harboring BMs from gastric and esophageal tumors, except cases with single lesions that are treated aggressively, have a poor prognosis. SRT (plus or minus surgery and whole brain radiotherapy) seems to give better results in terms of longer OS after brain relapse.

Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249(10):1357–69. doi:10.1007/s00415-002-0870-6.CrossRefPubMed

Fields RC, Strong VE, Gonen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104(12):1840–7. doi:10.1038/bjc.2011.175.CrossRefPubMedPubMedCentral

Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, Ajani JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology. 2014;86(5–6):336–9. doi:10.1159/000360703.CrossRefPubMedPubMedCentral

Weinberg JS, Suki D, Hanbali F, Cohen ZR, Lenzi R, Sawaya R. Metastasis of esophageal carcinoma to the brain. Cancer. 2003;98(9):1925–33. doi:10.1002/cncr.11737.CrossRefPubMed

Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer. 2015;113(12):1747. doi:10.1038/bjc.2015.458.CrossRefPubMedPubMedCentral

Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500. doi:10.1056/NEJM199002223220802.CrossRefPubMed

Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29(4):711–7.CrossRefPubMed

Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583–90. doi:10.1002/ana.410330605.CrossRefPubMed

Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, Duncan G, Skingley P, Foster G, Levine M. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470–6.CrossRefPubMed

10.

Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer. 2011;117(16):3630–40. doi:10.1002/cncr.25940.CrossRefPubMed

11.

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Menard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9. doi:10.1001/jama.2016.9839.CrossRefPubMedPubMedCentral

12.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91. doi:10.1001/jama.295.21.2483.CrossRefPubMed

13.

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44. doi:10.1016/S1470-2045(09)70263-3.CrossRefPubMed

14.

Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134–41. doi:10.1200/JCO.2010.30.1655.CrossRefPubMed

15.

Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP. Radiation dose–volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S20–7. doi:10.1016/j.ijrobp.2009.02.091.CrossRefPubMedPubMedCentral

16.

Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1–13. doi:10.1016/j.nbd.2003.12.016.CrossRefPubMed

17.

Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci. 2011;14(11):1398–405. doi:10.1038/nn.2946.CrossRefPubMedPubMedCentral

18.

Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology. 1998;139(4):1789–93. doi:10.1210/endo.139.4.5917.PubMed

19.

Petty MA, Lo EH. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol. 2002;68(5):311–23.CrossRefPubMed

20.

Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, Lotvall J, Nakagama H, Ochiya T. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716. doi:10.1038/ncomms7716.CrossRefPubMedPubMedCentral

21.

Marchetti D, Aucoin R, Blust J, Murry B, Greiter-Wilke A. p75 neurotrophin receptor functions as a survival receptor in brain-metastatic melanoma cells. J Cell Biochem. 2004;91(1):206–15. doi:10.1002/jcb.10649.CrossRefPubMed

22.

Marchetti D, Nicolson GL. Human heparanase: a molecular determinant of brain metastasis. Adv Enzyme Regul. 2001;41:343–59.CrossRefPubMed

23.

Nathoo N, Chahlavi A, Barnett GH, Toms SA. Pathobiology of brain metastases. J Clin Pathol. 2005;58(3):237–42. doi:10.1136/jcp.2003.013623.CrossRefPubMedPubMedCentral

24.

Ridgway LD, Wetzel MD, Marchetti D. Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells. J Cell Biochem. 2010;111(5):1299–309. doi:10.1002/jcb.22854.CrossRefPubMedPubMedCentral

25.

Ridgway LD, Wetzel MD, Ngo JA, Erdreich-Epstein A, Marchetti D. Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells. Mol Cancer Res. 2012;10(6):689–702. doi:10.1158/1541-7786.MCR-11-0534.CrossRefPubMed

26.

Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3(1):53–7.CrossRefPubMed

27.

Franco-Hernandez C, Martinez-Glez V, Arjona D, de Campos JM, Isla A, Gutierrez M, Vaquero J, Rey JA. EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors. Cancer Genet Cytogenet. 2007;173(1):63–7. doi:10.1016/j.cancergencyto.2006.09.023.CrossRefPubMed

28.

Abu Hejleh T, Deyoung BR, Engelman E, Deutsch JM, Zimmerman B, Halfdanarson TR, Berg DJ, Parekh KR, Lynch WR, Iannettoni MD, Bhatia S, Clamon G. Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World J Gastrointest Oncol. 2012;4(5):103–8. doi:10.4251/wjgo.v4.i5.103.CrossRefPubMedPubMedCentral

29.

Bartelt S, Momm F, Weissenberger C, Lutterbach J. Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. World J Gastroenterol. 2004;10(22):3345–8.CrossRefPubMedPubMedCentral

30.

Bowden G, Kano H, Tempel ZJ, Caparosa E, Monaco E 3rd, Niranjan A, Flickinger J, Luketich JD, Lunsford LD. Gamma knife radiosurgery for management of cerebral metastases from esophageal carcinoma. J Neurooncol. 2014;118(1):141–6. doi:10.1007/s11060-014-1408-3.CrossRefPubMed

31.

Feng W, Zhang P, Zheng X, Shan G, Chen M, Mao W. Neuroimaging and clinical characteristics of brain metastases from esophageal carcinoma in Chinese patients. J Cancer Res Ther. 2014;10(Suppl):296–303. doi:10.4103/0973-1482.151536.CrossRefPubMed

32.

Gabrielsen TO, Eldevik OP, Orringer MB, Marshall BL. Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. AJNR Am J Neuroradiol. 1995;16(9):1915–21.PubMed

33.

Giglio P, Weinberg JS, Forman AD, Wolff R, Groves MD. Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer. 2005;103(11):2355–62. doi:10.1002/cncr.21082.CrossRefPubMed

34.

Han JH, Kim DG, Chung HT, Kim CY, Park CK, Chung YS, Paek SH, Yoo MW, Kim BH, Jung HW. Radiosurgery for brain metastasis from advanced gastric cancer. Acta Neurochir. 2010;152(4):605–10. doi:10.1007/s00701-009-0554-4.CrossRefPubMed

35.

Hasegawa T, Kondziolka D, Hadjipanayis CG, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for CNS nongerminomatous germ cell tumors. Report of four cases. Pediatr Neurosurg. 2003;38(6):329–33. doi:10.1159/000070417.CrossRefPubMed

36.

Kanemoto A, Hashimoto T, Harada H, Asakura H, Ogawa H, Furutani K, Boku N, Nakasu Y, Nishimura T. Occurrence and clinical features of brain metastasis after chemoradiotherapy for esophageal carcinoma. J Radiat Res. 2011;52(4):509–15.CrossRefPubMed

37.

Kasakura Y, Fujii M, Mochizuki F, Suzuki T, Takahashi T. Clinicopathological study of brain metastasis in gastric cancer patients. Surg Today. 2000;30(6):485–90. doi:10.1007/s005950070112.CrossRefPubMed

38.

Kawabata R, Doki Y, Ishikawa O, Nakagawa H, Takachi K, Miyashiro I, Tsukamoto Y, Ohigashi H, Sasaki Y, Murata K, Ishiguro S, Imaoka S. Frequent brain metastasis after chemotherapy and surgery for advanced esophageal cancers. Hepatogastroenterology. 2007;54(76):1043–8.PubMed

39.

Khuntia D, Sajja R, Chidel MA, Lee SY, Rice TW, Adelstein DJ, Carlson TP, Saxton JP, Barnett GH, Suh JH. Factors associated with improved survival in patients with brain metastases from esophageal cancer: a retrospective review. Technol Cancer Res Treat. 2003;2(3):267–72.CrossRefPubMed

40.

Kim NH, Kim JH, Chin HM, Jun Kh. Leptomeningeal carcinomatosis from gastric cancer: single institute retrospective analysis of 9 cases. Ann Surg Treat Res. 2014;86(1):16–21. doi:10.4174/astr.2014.86.1.16.CrossRefPubMedPubMedCentral

41.

Koga H, Mukawa J, Miyagi K, Nakasone S, Kinjo T, Miyazato H, Ishikawa Y, Ito K, Higa Y. Treatment of metastatic brain tumor from esophageal carcinoma—report of four cases. Neurol Med Chir. 1991;31(8):518–22.CrossRef

42.

Kraszkiewicz M, Wydmanski J. Brain metastases from stomach cancer—the role of different treatment modalities and efficacy of palliative radiotherapy. Rep Pract Oncol Radiother. 2015;20(1):32–7. doi:10.1016/j.rpor.2014.08.003.CrossRefPubMed

43.

Lee JL, Kang YK, Kim TW, Chang HM, Lee GW, Ryu MH, Kim E, Oh SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Kim WK, Kim SH. Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol. 2004;66(1–2):167–74.CrossRefPubMed

44.

Lin L, Zhao CH, Ge FJ, Wang Y, Chen YL, Liu RR, Jia R, Liu LJ, Liu JZ, Xu JM. Patients with brain metastases derived from gastrointestinal cancer: clinical characteristics and prognostic factors. Clin Transl Oncol. 2016;18(1):93–8. doi:10.1007/s12094-015-1341-8.CrossRefPubMed

45.

Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003;26(2):165–70. doi:10.1097/01.COC.0000018175.95100.D1.CrossRefPubMed

46.

Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM. Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Dis Esophagus. 2015;28(8):772–81. doi:10.1111/dote.12276.CrossRefPubMed

47.

Matsunaga M, Wada S, Daa T, Harada K, Okamura K, Noguchi T. Long-term survival after resection of brain metastases from esophagogastric junction adenocarcinoma: report of two cases and review of the literature. Clin J Gastroenterol. 2014;7(3):213–8. doi:10.1007/s12328-014-0491-5.CrossRefPubMed

48.

Menendez JY, Bauer DF, Shannon CN, Fiveash J, Markert JM. Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system. J Neurooncol. 2012;109(3):513–9. doi:10.1007/s11060-012-0916-2.CrossRefPubMed

49.

Ogawa K, Toita T, Sueyama H, Fuwa N, Kakinohana Y, Kamata M, Adachi G, Saito A, Yoshii Y, Murayama S. Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer. 2002;94(3):759–64.CrossRefPubMed

50.

Oh SY, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ. Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol. 2009;15(40):5086–90.CrossRefPubMedPubMedCentral

51.

Okamura A, Takeuchi H, Sako H, Nakamura R, Takahashi T, Wada N, Kawakubo H, Saikawa Y, Omori T, Ozawa S, Kitagawa Y. Clinical features and prognostic factors of brain metastasis from esophageal carcinoma. Esophagus. 2014;11:217–22. doi:10.1007/s10388-014-0434-8.CrossRef

52.

Park YS, Chang JH, Chang JW, Park YG. The efficacy of gamma knife radiosurgery for advanced gastric cancer with brain metastases. J Neurooncol. 2011;103(3):513–21. doi:10.1007/s11060-010-0405-4.CrossRefPubMed

53.

Rades D, Dziggel L, Bartscht T, Gliemroth J. Predicting overall survival in patients with brain metastases from esophageal cancer. Anticancer Res. 2014;34(11):6763–5.PubMed

54.

Rice TW, Khuntia D, Rybicki LA, Adelstein DJ, Vogelbaum MA, Mason DP, Murthy SC, Blackstone EH. Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy? Ann Thorac Surg. 2006;82(6):2042–49, 2049.e2041–42. doi:10.1016/j.athoracsur.2006.06.089.

55.

Smith RS, Miller RC. Incidence of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol. 2011;17(19):2407–10. doi:10.3748/wjg.v17.i19.2407.CrossRefPubMedPubMedCentral

56.

Song Z, Lin B, Shao L, Zhang Y. Brain metastases from esophageal cancer: clinical review of 26 cases. World Neurosurg. 2014;81(1):131–5. doi:10.1016/j.wneu.2013.02.058.CrossRefPubMed

57.

Tomita H, Yasui H, Boku N, Nakasu Y, Mitsuya K, Onozawa Y, Fukutomi A, Yamazaki K, Machida N, Taku K, Todaka A, Taniguchi H, Tsushima T. Leptomeningeal carcinomatosis associated with gastric cancer. Int J Clin Oncol. 2012;17(4):361–6. doi:10.1007/s10147-011-0301-8.CrossRefPubMed

58.

Wadhwa R, Taketa T, Correa AM, Sudo K, Campagna MC, Blum MA, Komaki R, Skinner H, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher S, Hofstetter WL, Ajani JA. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013;85(4):204–7. doi:10.1159/000354736.CrossRefPubMed

59.

Yamamoto T, Kuroda J, Takezaki T, Shinojima N, Hide T, Makino K, Nakamura H, Yano S, Nishi T, Kuratsu J. Characteristics of brain metastases from esophageal carcinoma. Surg Neurol Int. 2014;5:137. doi:10.4103/2152-7806.141468.PubMedPubMedCentral

60.

Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Int J Cancer. 2016;139(7):1626–31. doi:10.1002/ijc.30200.CrossRefPubMed

61.

York JE, Stringer J, Ajani JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. Ann Surg Oncol. 1999;6(8):771–6.CrossRefPubMed

62.

Yoshida S. Brain metastasis in patients with esophageal carcinoma. Surg Neurol. 2007;67(3):288–90. doi:10.1016/j.surneu.2006.05.065.CrossRefPubMed

63.

Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer. 2015;113(5):716–21. doi:10.1038/bjc.2015.279.CrossRefPubMedPubMedCentral

64.

Chen MQ, Xu BH, Zhang YY. Analysis of prognostic factors for esophageal squamous cell carcinoma with distant organ metastasis at initial diagnosis. J Chin Med Assoc. 2014;77(11):562–6. doi:10.1016/j.jcma.2014.05.014.CrossRefPubMed

65.

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.CrossRefPubMed

66.

Waki F, Ando M, Takashima A, Yonemori K, Nokihara H, Miyake M, Tateishi U, Tsuta K, Shimada Y, Fujiwara Y, Tamura T. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol. 2009;93(2):205–12. doi:10.1007/s11060-008-9758-3.CrossRefPubMed

67.

Da Silva AN, Nagayama K, Schlesinger DJ, Sheehan JP. Gamma Knife surgery for brain metastases from gastrointestinal cancer. J Neurosurg. 2009;111(3):423–30. doi:10.3171/2008.9.JNS08281.CrossRefPubMed

68.

Trifiletti DM, Patel N, Lee CC, Romano AM, Sheehan JP. Stereotactic radiosurgery in the treatment of brain metastases from gastrointestinal primaries. J Neurooncol. 2015;124(3):439–46. doi:10.1007/s11060-015-1857-3.CrossRefPubMed

69.

Preusser M, Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Marosi C, Hejna M, Capper D, Von Deimling A, Schoppmann SF, Birner P. Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. Anticancer Res. 2013;33(3):1065–71.PubMed

Titel: Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review
verfasst von: Michele Ghidini
Fausto Petrelli
Jens Claus Hahne
Annamaria De Giorgi
Laura Toppo
Claudio Pizzo
Margherita Ratti
Sandro Barni
Rodolfo Passalacqua
Gianluca Tomasello
Publikationsdatum: 01.04.2017
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-017-0919-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Low microchimeric cell density in tumors suggests alternative antineoplastic mechanism

Oxidative stress indicated by elevated expression of Nrf2 and 8-OHdG promotes hepatocellular carcinoma progression

Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma

Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy

Percutaneous needle biopsy of mediastinal masses under C-arm conebeam CT guidance: diagnostic performance and safety

Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie